Related Experiment Videos
Management of bacterial meningitis
C A Hart1, L E Cuevas, O Marzouk
1Department of Medical Microbiology, University of Liverpool, UK.
Abstract:
In developed countries the mortality from bacterial meningitis acquired outside the neonatal period is relatively low. In contrast, in developing countries it is often higher (20%-40%). In developed countries despite (and perhaps because of) the introduction of increasingly potent antimicrobials, the morbidity of bacterial meningitis has remained high. For example, up to 25% of patients with Haemophilus influenzae meningitis have some form of neurological deficit. Neisseria meningitidis is the major cause of bacterial meningitis in many areas of the world. A clone of Group A meningococcus has spread from China to cause the most recent major epidemic in Sub-Saharan Africa. Group B meningococcal infections causing sporadic meningitis are increasing in parts of Europe and South America. The mortality from meningococcal disease is greatest when there is a septicaemic component to the infection. Although antimicrobial chemotherapy is of major importance some adjuncts to therapy are beneficial. High dose corticosteroid therapy has been shown to decrease mortality in pneumococcal meningitis in an uncontrolled study and to speed recovery and decrease neurological sequelae in H. influenzae meningitis. Nevertheless to prevent infection would be of greater benefit. Prevention can be achieved by either chemoprophylaxis or immunoprophylaxis. Although safe and effective vaccines are available to prevent pneumococcal, H. influenzae (Hib) and Groups A and C meningococcal meningitis; apart from the protein conjugate Hib vaccine they are less effective in children under two years of age. There is no effective vaccine to protect against group B meningococcal meningitis.
Insights
Bacterial meningitis poses a higher mortality risk in developing nations. While vaccines exist for some types, like Haemophilus influenzae (Hib) and meningococcal meningitis (Groups A and C), none are effective against Group B meningococcal infections, highlighting a critical prevention gap.
Area of Science:
- Infectious Diseases
- Microbiology
- Epidemiology
Background:
- Bacterial meningitis mortality is higher in developing countries (20-40%) compared to developed nations.
- Neurological deficits remain common (up to 25%) in survivors of bacterial meningitis, even with advanced antimicrobials.
- Neisseria meningitidis is a leading cause of bacterial meningitis globally, with epidemic strains and increasing Group B infections observed.
Purpose of the Study:
- To review the current landscape of bacterial meningitis, focusing on mortality, morbidity, and prevention strategies.
- To highlight the limitations of existing vaccines, particularly for young children and against specific strains like Group B meningococcus.
- To discuss the role of adjunctive therapies and the importance of preventative measures.
Main Methods:
- Literature review of bacterial meningitis epidemiology, treatment outcomes, and vaccine efficacy.
- Analysis of mortality and morbidity data across different geographical regions and causative agents.
- Evaluation of current prevention strategies, including chemoprophylaxis and immunoprophylaxis.
Main Results:
- Bacterial meningitis mortality varies significantly, with higher rates in developing countries.
- Neurological sequelae are a significant concern, persisting despite potent antimicrobial treatments.
- Effective vaccines exist for pneumococcal, Hib, and A/C meningococcal meningitis, but efficacy is limited in children under two. No vaccine is available for Group B meningococcal meningitis.
Conclusions:
- Prevention through vaccination and chemoprophylaxis is paramount for reducing bacterial meningitis burden.
- Development of broadly effective vaccines, especially against Group B meningococcus and for young children, is a critical unmet need.
- Adjunctive therapies like corticosteroids may offer benefits in specific meningitis types, but prevention remains the ultimate goal.